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Objectives: Hypothermia reduces intracranial hypertension in 
patients with traumatic brain injury but was associated with 
harm in the Eurotherm3235Trial. We stratified trial patients by 
International Mission for Prognosis and Analysis of Clinical Tri-
als in [Traumatic Brain Injury] (IMPACT) extended model sum 
scores to determine where the balance of risks lay with the 
intervention.
Design: The Eurotherm3235Trial was a randomized controlled 
trial, with standardized and blinded outcome assessment. 
Patients in the trial were split into risk tertiles by IMPACT 
extended model sum scores. A proportional hazard analysis for 
death between randomization and 6 months was performed by 
intervention and IMPACT extended model sum scores tertiles in 
both the intention-to-treat and the per-protocol populations of 
the Eurotherm3235Trial.
Setting: Forty-seven neurologic critical care units in 18 countries.
Patients: Adult traumatic brain injury patients admitted to inten-
sive care who had suffered a primary, closed traumatic brain 
injury; increased intracranial pressure; an initial head injury less 
than 10 days earlier; a core temperature at least 36°C; and an 
abnormal brain CT.
Intervention: Titrated Hypothermia in the range 32-35°C as the 
primary intervention to reduce raised intracranial pressure.
Measurements and Main Results: Three hundred eighty-six patients 
were available for analysis in the intention-to-treat and 257 in the 
per-protocol population. The proportional hazard analysis (inten-
tion-to-treat and per-protocol populations) showed that the treat-
ment effect behaves similarly across all risk stratums. However, 
there is a trend that indicates that patients in the low-risk group 
could be at greater risk of suffering harm due to hypothermia.
Conclusions: Hypothermia as a first line measure to reduce intra-
cranial pressure to less than 20 mm Hg is harmful in patients with 
a lower severity of injury and no clear benefit exists in patients with 
more severe injuries. (Crit Care Med ; XX:00–00)
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Experimental studies of hypothermia delivered after all forms of acute brain injury show neurologic benefit (infarct volume and neurologic behavior scores), even 
when the induction of hypothermia is delayed after injury 
and temperature reduction is modest (1). Therapeutic hypo-
thermia (TH) has previously been tested after traumatic brain 
injury (TBI) to assess prophylactic neurologic protection (2).
The Eurotherm3235Trial was a large randomized controlled 
trial that tested TH as the primary intervention (after stage I inter-
ventions) to reduce intracranial pressure (ICP) below 20 mm Hg 
after TBI compared with standard care (control). In this way, TH 
was delivered in a dosage (depth and duration) dictated by a bio-
marker of the injury process, ICP, to reduce the burden of possible 
complications in milder injury and keeping colder temperatures 
for more severe injury/brain swelling. The intention-to-treat 
(ITT) analysis showed higher mortality and worse outcomes with 
TH compared with standard care, and the trial was stopped early 
because of likely futility and the potential for harm (3).
Postpublication sentiment has considered that TH could still 
be used in the TBI patients with refractory elevated ICP (4).
TBI is a heterogeneous disease with respect to cause, pathology, 
severity, and prognosis. This causes considerable uncertainty in 
the expected outcome of individual patients. Prognostic models 
can be used to combine different characteristics of an individual 
patient to predict outcome. The choice of model depends upon 
the clinical setting and case-mix of the population under study. 
The International Mission for Prognosis and Analysis of Clinical 
Trials in TBI (IMPACT) models were developed on patients with 
moderate and severe TBI and mostly from high-income coun-
tries (5, 6). Given the data collected in Eurotherm3235Trial, the 
IMPACT extended model sum score (IEMSS) was selected as the 
most representative calculation to determine the baseline risk 
score for the patients, in order to assess the relationship between 
severity and the intervention effect.
The aim of this analysis is to assess the relationship between 
IEMSS and the intervention effect.
MATERIALS AND METHODS
On May 29, 2013, the Data Monitoring Committee (DMC) 
requested an additional analysis of the primary endpoint and 
mortality by IEMSS tertiles as a further participant safeguard. The 
first such IEMSS analysis was delivered on July 24, 2013, and after 
review, the DMC members decided to keep the subgroup analysis 
by IEMSS permanently in the DMC report. This analysis was not 
included in the final trial statistical analysis plan (SAP) and has 
not been published before but may provide important informa-
tion to clinicians about the choice of therapy for ICP reduction.
Interventions and Study Procedures
The Eurotherm3235Trial was a pragmatic, randomized con-
trolled trial, with standardized and blinded outcome assess-
ment (7). Intracranial hypertension was defined in accordance 
with the Brain Trauma Foundation (BTF) guidelines, 2007 (8).
In brief, eligible participants with ICP greater than 
20 mm Hg were randomized to either standard care (includ-
ing mechanical ventilation and increased sedation) with 
osmotherapy (control group) or standard care with titrated 
TH as the primary intervention to reduce ICP less than 20 mm 
Hg. Hypothermia was maintained for at least 48 hours and 
continued for as long as was necessary to maintain ICP less 
than or equal to 20 mm Hg, core temperature was to remain 
within the limits 32–35°C. Rewarming was then considered 
provided the ICP remained less than or equal to 20 mm Hg.
Ethical approval was obtained from Scotland A Research 
Ethics Committee (REC) as the lead REC (09/MRE00/34) and 
additionally Bradford REC (09/H1302/44) and ethics commit-
tees in a further 14 countries. Due to their incapacitated state, 
it was not possible to obtain consent directly from potential 
participants. Informed consent was therefore sought from each 
eligible patient’s nearest relative or another person designated 
to give consent on the patient’s behalf.
Outcomes
The primary outcome measure was the Extended Glasgow 
Outcome Scale (GOSE) score at 6 months after injury. The 
GOSE was assessed by a structured questionnaire (by post 
or interview), and a blinded investigator scored all outcomes 
according to a standardized approach (9). The 6-month mor-
tality was a secondary outcome.
Per-Protocol (PP) Population
The PP population comprises those members of the ITT pop-
ulation who completed the study without a major protocol 
violation and who complied adequately with the administered 
intervention. Intervention compliance was decided using the 
following strategy and is described in the trial’s SAP:
Step 1. If a patient was allocated to an intervention, then 
they should have received the allocated intervention.
Step 2. If a patient was allocated to control group, then their 
core temperature should be strictly equal to or greater than 
36°C for at least 80% of the 48 possible temperature observa-
tions for the first 48 hours from randomization or until death 
(for whichever event occurred first).
Step 3. If a patient was allocated to hypothermia group, then 
their core temperature should be strictly greater than or equal to 
32°C and strictly less than 35°C for at least 80% of the 44 pos-
sible temperature observations from 4 hours after hypothermia 
started until the first 48 hours from randomization or until death 
(for whichever event occurred first). No barbiturate infusion 
was permitted within the first 48 hours from randomization.
IEMSS
Sum scores were calculated for all participants using the 
IMPACT extended model (10) using age, motor score, pupil-
lary reactivity, Marshall CT classification, presence of traumatic 
subarachnoid hemorrhage on CT, and extradural hematoma 
on CT (Fig. S1, Supplemental Digital Content 1, http://links.
lww.com/CCM/C471—legend, Supplemental Digital Content 
2, http://links.lww.com/CCM/C472). These data were rou-
tinely collected in all subjects and available in the Case Report 
Form. Hypoxia and hypotension values were not recorded in 
the Eurotherm3235Trial and were assigned “0” points (10).
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The IEMSS was ordered and split into tertiles in order to gen-
erate a baseline risk profile for each patient (low, medium, and 
high). The population for the calculation of the risk and subse-
quent tertile allocation is the ITT population, so when data are 
filtered by compliance (i.e., PP population), the tertiles will not 
necessarily remain equal in terms of numbers in each. The bound-
aries of the (statistical) tertiles were adjusted to group patients 
with the same risk score (IEMSS) into the same risk category, that 
is, if a patient was in the low-risk category but had an IEMSS and 
the same risk calculation as any patient in the medium category, 
then they were reallocated to medium-risk tertile. Similar adjust-
ments were made for medium-risk participants, in a way that 
always made the risk tertile worse instead of better.
The probabilities of 6-month outcomes were calculated as (10):
Probability of mortality
1 1 exp 2 98  256 sum score e
=
+ − +/ . . *0 xtended model( )( )( )
Probability of unfavorable
1 1 exp 2 1   276 sum score 
=
+ − +/ . . *0 0 extended model( )( )( )
Statistical Methods
The distribution of the 6-month GOSE between the groups 
(hypothermia vs control) by IEMSS was compared using ordi-
nal regression, adjusting for time from injury (< 12 vs ≥ 12 hr), 
including an interaction term between IEMSS and the interven-
tion. Also a nonadjusted model was fitted. The eight-point GOSE 
was collapsed to six categories by pooling death with vegetative 
state and lower severe disability. Also, the conventional dichoto-
mized split of the GOSE as lower moderate disability or better 
(favorable) versus upper severe disability or worse (unfavorable) 
was analyzed. For the difference in mortality, Cox proportional 
hazards regression (fitting intervention, IEMSS, and an interac-
tion term) was used, and its assumptions were verified by visual 
inspection of the survival curves (11). Analyses were performed 
with SAS software, version 9.4 (SAS Institute, Cary, NC). A level 
of statistical significance p value of less than 0.05 was used.
RESULTS
Data from 386 patients were available for analysis for the ITT 
population. Data from 257 patients were available for analysis 
for the PP population (Table 1). Demographic and baseline 
characteristics by the IEMSS tertiles are presented in Tables S1 
and S2 (Supplemental Digital Content 2, http://links.lww.com/
CCM/C472) for the ITT population. The GOSE and mortality 
rate distribution by intervention are presented in Figure 1. The 
analysis for the GOSE and mortality rate showed no significant 
interaction effect between the intervention and the IEMSS ter-
tiles for the ITT and PP populations (Figs. 2 and 3).
The adjusted and nonadjusted analysis for the collapsed and 
dichotomized GOSE showed no statistically significant difference 
between the intervention for each IEMSS tertile. The odds ratio 
favored “control” over hypothermia in all comparisons (Fig. 2).
The proportional hazard analysis for death between ran-
domization and 6 months by IEMSS tertile and intervention 
behaved similarly across high- and medium-risk stratums, but 
there is a change in the magnitude of the effect in the lower risk 
cohort (Fig. 3).
The Glasgow Coma Scale (GCS) sum score at admission was 
less than or equal to 8 in approximately 50% of the patients in 
lower and medium-risk tertiles and just over 20% of patients 
were characterized as having a mild TBI (GCS, 13–15) on hos-
pital admission. These were patients who suffered secondary 
deterioration, and a greater proportion of patients had neuro-
surgery (CT Marshall score V) in the medium- and high-risk 
tertiles but the proportions were similar, 25% and 19%, respec-
tively (Table S2, Supplemental Digital Content 2, http://links.
lww.com/CCM/C472).
Intracranial pathology (Table S3, Supplemental Digital 
Content 2, http://links.lww.com/CCM/C472): More extradural 
hematomas were evident in the low-risk tertiles compared with 
medium- and high-risk tertiles (as expected), with more diffuse 
axonal injury in the high-risk ITT cohorts and more traumatic 
subarachnoid hemorrhage in high (and medium) PP cohorts.
Intracranial neurosurgery (Table S4, Supplemental Digital 
Content 2, http://links.lww.com/CCM/C472): More extradural 
TABLE 1. Eurotherm3235Trial Protocol Compliance
Eurotherm3235Trial Compliance Categories
Allocated  
Hypothermia
Allocated  
Control Overall
Intention-to-treat population (n, %) All subjects 195 (100) 192 (100) 387 (100)
Per-protocol population (n, %) No 70 (35.9) 60 (31.3) 130 (33.6)
Yes 125 (64.1) 132 (68.7) 257 (66.4)
Intervention delivered (n, %) Hypothermia 187 (95.9) 5 (2.6) 192 (49.6)
Control 8 (4.1) 187 (97.4) 195 (50.4)
Intervention compliance (n, %) Missing data 2 0 2
Yes 125 (64.8) 132 (68.8) 257 (66.8)
No 68 (35.2) 60 (31.3) 128 (33.2)
Treatment compliance to determine the per-protocol group was decided using a strategy that is described in the text and in more detail in the 
trial’s statistical analysis plan.
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hematoma evacuations occurred in the low-risk tertiles, but 
the trend was otherwise for more operative interventions in 
the medium- and high-risk tertiles.
DISCUSSION
In summary, the analysis split by IEMSS tertiles showed a gen-
eral trend toward harm for both the ITT and the PP populations 
with hypothermia. Furthermore, when the IEMSS was used for 
risk stratification of the PP population, the largest interven-
tion effect was evident in the low-risk IEMSS group of patients 
who were theoretically least likely to suffer death (9% mean 
probability) and unfavorable 
outcomes (18% mean proba-
bility) (Table 2). Consequently, 
it was the lowest risk of death 
group where the (potentially 
adverse) intervention effect was 
most evident and this interven-
tion effect was greatest when 
the intervention was deliv-
ered according to the protocol 
(Fig. 3) (Fig. S2, Supplemental 
Digital Content 3, http://links.
lww.com/CCM/C473—legend, 
Supplemental Digital Con-
tent 2, http://links.lww.com/
CCM/C472). The patients 
with the lowest IMPACT scores 
are the youngest patients in 
the trial and when ICP is dif-
ficult to control at stage II, and 
because of the perception they 
have most to lose, they are the 
group in whom hypothermia is 
often considered as a stage III 
(last ditch) intervention.
Analysis of intracranial 
lesion(s) and neurosurgery 
intervention(s) did not reveal 
imbalances that could account 
for these findings. Therefore, 
the results of this trial could be 
due to either a biological effect 
of the hypothermia interven-
tion or an imbalance in cointer-
ventions, including a restriction 
in the use of barbiturate infu-
sion with hypothermia.
Prediction models are 
important tools for heteroge-
neity adjustment in clinical 
trials and for the evaluation 
of the quality of care deliv-
ered to patients with TBI. The 
Corticosteroid Randomisation 
After Significant Head Injury 
(CRASH) and IMPACT prognostic models have been devel-
oped using contemporary approaches to large datasets (5, 10, 
12) and were externally validated reciprocally (10, 13, 14). 
The IMPACT model was validated against the CRASH trial 
data that similarly had no data on hypoxia and hypotension. 
We therefore followed an established methodology that dem-
onstrated good agreement between the IMPACT EMSS and 
CRASH data for assessment of severity of injury.
Although randomization was extended to 10 days following 
review of the pilot data, the admission characteristics were used 
for calculation of baseline prognostic risk. The demographics 
Figure 1. Bar charts showing the distribution of mortality and dichotomized Glasgow Outcome Scale Extended (GOSE) 
into favorable and unfavorable outcomes, by intention-to-treat (ITT) and per-protocol (PP) participant populations (four 
bar charts to one figure). A, Occurrence rate of death, ITT population. B, Occurrence rate of death, PP population. C, 
Glasgow Outcome Scale Extended, ITT population. D, Glasgow Outcome Scale Extended, PP population.
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Figure 2. Forest plot of the Eurotherm3235Trial Glasgow Outcome Scale Extended (GOSE) by intervention and International Mission for Prognosis and 
Analysis of Clinical Trials in [Traumatic Brain Injury] (IMPACT) Extended Model Sum Score (IEMSS). Data are analyzed by 1) collapsed ordinal analysis of 
the GOSE with death, vegetative state, and lower severe disability combined so as not to give credit for severely impaired survival and 2) a dichotomized 
analysis. Both analyses are presented with adjusted and nonadjusted (for baseline risk) outcomes. A, Intention-to-treat (ITT) Population. GOSE statistical 
analysis by intervention and IEMSS. B, Per-protocol (PP) population. GOSE statistical analysis by intervention and IEMSS.
Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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of these patients were similar to IMPACT, and the model is 
therefore applicable to the Eurotherm3235Trial cohort.
There were no important differences between the three ter-
tiles for ICP control at 20 or 25 mm Hg thresholds or for new 
infection. When the PP patients were examined, the effect of 
hypothermia was to significantly increase mortality in the low-
est risk tertile. The better outcome potential of the lowest risk 
tertile unmasked the harm of the intervention. However, no 
benefit was evident in the medium- and high-risk tertiles in 
any analyses (adjusted and nonadjusted) and the odds ratio 
always favored control.
The Eurotherm3235Trial protocol resulted in the use of cool-
ing at a relatively early stage for ICP control, once the first line 
measures of sedation, positioning, and optimization of arterial 
blood gas tensions had failed. One criticism of the trial is that 
in many ICUs hypothermia is applied later, once other mea-
sures such as paralysis and hypertonic treatments have failed. 
The rational for this trial design was to reduce the confounding 
effects of multiple, poorly evaluated hypertonic therapies (where 
the benefits and harms are not known) in the hypothermia 
group. The restriction of cooling to cases in which ICP control 
is more refractory to treatment might in effect be reserving it for 
those with a predicted IEMSS high risk of death. Based on these 
data our analysis did not demonstrate a benefit to this tertile.
At the inception of the Eurotherm3235Trial, we considered 
that if TH was targeted as a biomarker of the injury process, 
this would lead to a better balance of depth and duration of 
hypothermia to injury severity. Raised ICP was considered an 
appropriate biomarker of TBI as it is a life-threatening com-
plication of TBI and can result in compromised cerebral cir-
culation, brain stem compression, and brain death. Increased 
ICP is strongly associated with poorer outcomes after TBI 
and therefore has been regarded as a target for therapy (8).
ICP monitoring is generally viewed as the cornerstone 
of care in these patients and is recommended in all mod-
ern guidelines for treatment of TBI. However, studies show-
ing beneficial effects of this approach are lacking. The newly 
released fourth edition of the BTF guidelines (15) recommend 
treating ICP greater than 22 mm Hg because values above this 
level are associated with increased mortality. An important 
finding of the Eurotherm study was the efficacy of contempo-
rary critical care management to control ICP after TBI. The 
Eurotherm3235Trial screening log showed ICP was controlled 
with first line measures in 84% of patients.
What is the benefit of ICP monitoring over and above clini-
cal examination and cross-sectional imaging? Chesnut et al 
(16) and Cremer et al (17) showed no outcome benefit from 
ICP monitoring and an increased length of ICU and hospital 
stay. Previous studies that have evaluated interventions that 
reduce ICP are neutral or show a trend toward harm. These 
include Decompressive Craniectomy in Diffuse Traumatic 
Brain Injury) (DECRA), CRASH, Decompressive Craniectomy 
for Traumatic Intracranial Hypertension (RescueICP), and 
previous studies of TH (18–22).
Figure 3. Forest plot of the Eurotherm3235Trial mortality by intervention and International Mission for Prognosis and Analysis of Clinical Trials in [Traumatic 
Brain Injury] (IMPACT) Extended Model Sum Score. Data are presented as a proportional hazard analysis for death. ITT = intention-to-treat, PP = per-protocol.
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Historically, the more commonly investigated use of hypo-
thermia following TBI has been for neuroprotection, the inter-
vention being applied as soon as is practicable after injury. One 
such multicenter RCT is ongoing (Prophylactic Hypothermia 
Trial to Lessen Traumatic Brain Injury [POLAR-RCT]). 
The larger RCTs such as National Acute Brain Injury Study: 
Hypothermia (NABIS H) II (20), and B-HYPO (24) failed 
to demonstrate a neuroprotective effect of hypothermia and 
many reasons have been suggested for this.
The Eurotherm3235Trial was a study of the use of hypo-
thermia to control ICP. We tested a widely used intervention 
to reduce ICP below an internationally recognized thresh-
old and that strategy led to significantly poorer outcomes, 
increased mortality and, when assessed on a PP basis, harmed 
TABLE 2. Predicted Mortality and Predicted Dichotomized Glasgow Outcome Score 
Extended Probabilities by International Mission for Prognosis and Analysis of Clinical 
Trials in [Traumatic Brain Injury] Extended Model Sum Score Divided into Three Tertiles
International Mission for Prognosis 
and Analysis of Clinical Trials in 
[Traumatic Brain Injury] Extended 
Model Sum Scores Tertile
Allocated  
Intervention n Mean
Lower 95% CI 
for Mean
Upper 95% CI 
for Mean sd
ITT population probability of mortalitya
 Low Hypothermia 57 0.100 0.093 0.107 0.025
Control 56 0.092 0.086 0.099 0.023
 Mid Hypothermia 56 0.187 0.179 0.196 0.031
Control 64 0.192 0.184 0.199 0.031
 High Hypothermia 82 0.439 0.405 0.473 0.155
Control 72 0.444 0.411 0.478 0.143
ITT population probability of unfavorable outcome
 Low Hypothermia 57 0.220 0.206 0.234 0.053
Control 56 0.204 0.192 0.217 0.048
 Mid Hypothermia 56 0.383 0.369 0.397 0.052
Control 64 0.390 0.377 0.403 0.051
 High Hypothermia 82 0.677 0.648 0.707 0.135
Control 72 0.686 0.657 0.715 0.124
PP population probability of mortality
 Low Hypothermia 32 0.092 0.083 0.102 0.026
Control 41 0.092 0.085 0.100 0.024
 Mid Hypothermia 40 0.186 0.176 0.197 0.033
Control 41 0.190 0.180 0.199 0.030
 High Hypothermia 53 0.426 0.385 0.467 0.149
Control 50 0.453 0.410 0.495 0.149
PP population probability of unfavorable outcome 
 Low Hypothermia 32 0.184 0.184 0.224 0.056
Control 41 0.189 0.186 0.221 0.050
 Mid Hypothermia 40 0.363 0.363 0.398 0.055
Control 41 0.372 0.372 0.403 0.049
 High Hypothermia 53 0.631 0.631 0.703 0.131
Control 50 0.656 0.656 0.728 0.126
ITT = intention-to-treat, PP = per-protocol.
a Probability calculated using the International Mission for Prognosis and Analysis of Clinical Trials in [Traumatic Brain Injury] “extended model,” Variables hypoxia 
and hypotension were set to “no” for all patients.
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participants considered at lowest risk of death, when compared 
with medical care that aimed to do the same. Stratification of 
patients according to the IEMSS (10) showed that the burden 
of harm was in the low risk of poor outcome and/or death 
cohort, with no evidence of benefit across any severity tertile.
Implications of All the Available Evidence
The four largest trials of TH after TBI all show evidence of 
increased mortality (3, 20, 21, 23) with TH. Therefore, despite 
optimistic Systematic Reviews (2), TH should not be used after 
TBI, for neuroprotection or to reduce ICP (4) outside of clini-
cal trials.
CONCLUSIONS
Hypothermia as a first line measure to reduce ICP to less than 
20 mm Hg is potentially harmful in patients with a lower sever-
ity of injury assessed by IEMSS and no clear benefit exists in 
patients with more severe injuries. We recommend against the 
use of hypothermia after TBI and in particular in the context 
of ICP reduction.
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